This is in part because of complex genomic rearrangements and nonconventional mutagenesis of key driver genes (KRAS, TP53, SMAD4, and CDKN2A) resulting in rapid tumor progression.25 These genetic and molecular differences may lead to differences in tissue tropism, and subsequently, differences in response to therapy and patient outcomes. Here, KRAS is linked to neoplasm.